Valeant Will Release First-Quarter 2018 Financial Results On May 8

Valeant Will Release First-Quarter 2018 Financial Results On May 8

LAVAL, Quebec, April 6, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") will release its first-quarter 2018 financial results on Tuesday, May 8, 2018. Valeant will host a conference call and live web cast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Valeant web site prior to the start of the call.

    Conference Call
     Details

    Date:             Tuesday, May 8, 2018

    Time:             8:00 a.m. EDT

    Webcast:          http://ir.valeant.com/events-and-presentations

    Participant Event
     Dial-in:         (844) 428-3520 (North America)

                      (409) 767-8386 (International)

    Participant
     Passcode:                                                       6185877

    Replay Dial-in:   (855) 859-2056 (North America)

                      (404) 537-3406 (International)

    Replay Passcode:  6185877 (replay available until July 8, 2018)

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.valeant.com.

    Investor Contact:          Media Contact:

    Arthur Shannon             Lainie Keller

    arthur.shannon@valeant.com lainie.keller@valeant.com

    (514) 856-3855             (908) 927-0617

View original content with multimedia:http://www.prnewswire.com/news-releases/valeant-will-release-first-quarter-2018-financial-results-on-may-8-300624661.html

SOURCE Valeant Pharmaceuticals International, Inc.